FindTrial
Sign In

A multicentric observational study to see how the starting point of bowel cancer and the cancer?s DNA affect the chances of cancer returning after liver surgery

The impact of primary tumour location and molecular profile on recurrence patterns following liver resection for colorectal liver metastases (CRLM): a multicentre cohort study (BIO-CRLM Study) - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/09/094632
Enrollment
5000
Registered
2025-09-11
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C210- Malignant neoplasm of anus, unspecified Health Condition 2: C189- Malignant neoplasm of colon, unspecified Health Condition 3: C229- Malignant neoplasm of liver, not specified as primary or secondary Health Condition 4: C19- Malignant neoplasm of rectosigmoidjunction Health Condition 5: C20- Malignant neoplasm of rectum

Interventions

Intervention1: Nil: Nil Control Intervention1: NIL: NIL

Sponsors

Tata Memorial Hospital
Lead Sponsor
Newcastle University Freeman Hospital Newcastle upon Tyne UK
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1. Adult patients aged 18 years and above at the time of liver surgery with histologically confirmed colorectal adenocarcinoma and liver metastases. 2. Patients who underwent curative-intent liver resection from January 2017 to October 2023. 3.Known molecular profile for at least 1 of the following: KRAS/NRAS, BRAF or MSI. Ideally, KRAS/NRAS and BRAF status will be known for all patients after 2010.

Exclusion criteria

Exclusion criteria: 1. Incomplete macroscopic (R2) resection 2.Concomitant unresectable extrahepatic disease 3.Patients who have undergone treatment for extrahepatic disease (e.g. lung ablation or resection) 4. Insufficient data for key variables (unknown primary, lack of follow up data) 5.Non-adenocarcinoma histology

Design outcomes

Primary

MeasureTime frame
impact of primary tumour location and tumour molecular profile on patterns of recurrence and survival following curative-intent liver resection for CRLMTimepoint: upto 18 months after surgery date—

Secondary

MeasureTime frame
predictors of isolated liver-only recurrence vs. lung-only recurrence versus disseminated diseaseTimepoint: upto 18 months after surgery date;use of systemic therapy (downstaging or post-resection palliative) varies between patients with different primary tumour sites, and whether the benefit of chemotherapy differs by molecular subtypeTimepoint: upto 18 months after surgery date—

Countries

Australia, Canada, Germany, India, United Kingdom

Contacts

Public ContactDr Shraddha Patkar

Tata Memorial Hospital

drshraddhapatkar@gmail.com9820074818

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026